SHORT ANSWER
Yes. FTC reads an advertisement by its net impression, and it says that includes the product name, not just the body copy. FDA reads intended use from labeling, and a name is labeling. In its warning letters FDA has quoted product names built from outcomes, brand-name drugs, and doses as evidence of human therapeutic intent, before reaching the description at all.
This material is general educational information as of the “last reviewed” date. It is not legal advice and may not reflect later developments or facts specific to your business. Links are provided so readers can inspect the primary or official sources.
01 / WHY A NAME COUNTS
Two agencies, one conclusion: the name is part of the message
The FTC's Health Products Compliance Guidance tells marketers to assess the whole advertisement, including the product name, charts, and images, because consumers take away a net impression from all of it. A qualified paragraph under an unqualified name does not change what the shopper read first.
FDA arrives at the same place by a different route. Under 21 CFR § 201.128, intended use is shown by labeling, advertising, and the circumstances of distribution. A product name printed on a vial, a listing, or a collection page is labeling. When the name says what the product does to a body, the name is evidence of intended use on its own.
The letters quoted below describe what FDA observed on particular sites on particular dates. They illustrate patterns; they do not decide any other storefront.
02 / THE PATTERNS
A working list of naming patterns FDA has quoted
RUO Clear tagged the 1,160 marketing phrases FDA quoted across 185 peptide, GLP-1, and research-chemical warning letters from 2021 to mid-2026. Names and name-like labels recur in a handful of shapes. Examples below are quoted from the letters, with the company and letter date.
- Outcome in the name. A blend sold as “CagriLean” (Xcel Research, December 10, 2024): the name promises leanness before the description says anything. Headings and collection labels do the same work: “Muscle Growth and Differentiation” (Atomix, December 12, 2025) and “Maintaining Heart Health with Cardarine” (SARMS America, December 12, 2025).
- Approved brand in the name. “5mg Tirzepatide (Mounjaro) 5mg” (USApeptide.com, February 26, 2025). Brand-equivalence phrasing appears in 76 quoted lines across 45 letters in RUO Clear's tagging, and FDA treats it as a statement that the product is the drug.
- Dose in the name. “GW-501516 Cardarine – 20 MG/ML” and “MK-2866 Ostarine SARM – 20 MG/ML” (Umbrella, May 18, 2021). A concentration is neutral in a catalog; a per-serving dose reads as instructions for use. Dose-in-name lines appear 38 times across 6 letters in the corpus.
- Protocol, kit, or stack in the name. “Standard Dose Protocol for Tirzepatide Research” (Helix Chemical Supply, February 7, 2024). A name that implies a regimen implies administration.
- Category and collection names. “Weight Loss,” “Recovery,” and “Anti-Aging” as menu items or collection slugs describe the intended use of everything filed under them.
- Adjacent names. Bacteriostatic water, insulin syringes, and “injection kits” listed beside the peptides. FDA cited bundled supplies in 15 letters in RUO Clear's tagging; the supply's name tells the reader the route of administration.
The numbers describe how the quoted phrases were categorized during compilation. They show the range of what FDA has quoted, not the odds of enforcement.
03 / NEUTRAL NAMING
What a name looks like when it carries no claim
This is a recommended control, not a rule, and a neutral name does not settle anything on its own. It removes one input to the net impression so the rest of the page can be judged on its own terms.
- Compound name as the identifier: the chemical or common research name, not a coined brand that hints at an effect.
- Quantity and form, not dose: “10 mg vial, lyophilized” describes what is in the container; “10 mg per dose” describes what to do with it.
- Lot or batch identifier where it fits, which is what a research buyer actually needs.
- No approved-drug brand anywhere in the name, the slug, or the comparison line.
- Collections named by chemistry or catalog structure, not by the body system or outcome a shopper might want.
04 / WHERE NAMES HIDE
The name lives in more places than the product title
A rename that stops at the title leaves the old name in a dozen fields. FDA has cited website metatags and search keywords as evidence of intended use in 2 letters in RUO Clear's corpus, which means the fields no shopper sees still count.
- URL slugs and permalinks, which often keep the original name after a title edit
- Meta titles and descriptions generated from the old name
- Image file names and alt text
- Breadcrumbs and category paths
- Cross-sell and “frequently bought together” labels
- Search keywords, tags, and structured-data product names
- Old blog posts and social captions that link to the product by its former name
05 / REVIEW CHECKLIST
How to review a catalog for names that claim
Work the catalog as a list, not page by page. Export every product title, slug, collection, tag, and image alt text, then read the export cold.
- Does any name contain an outcome word: lean, burn, repair, sleep, growth, recovery, glow, calm?
- Does any name, slug, or comparison line contain an approved drug's brand name?
- Does any name state a dose rather than a quantity?
- Does any name imply a protocol, cycle, stack, or kit?
- Are collections named by body system or goal rather than by chemistry?
- Do adjacent products supply a route of administration, and are they named that way?
- After a rename, did the slug, meta title, alt text, and structured data change with it?
QUESTIONS
Related questions
If the name is neutral but the description makes claims, does the name help?
Not much. Both agencies read the whole presentation. A neutral name beside an outcome-heavy description leaves the net impression about where it was.
Is the compound name itself a problem?
The chemical or common research name identifies the substance; it does not describe an effect. The patterns FDA quoted add something to that name: an outcome, a brand, a dose, or a protocol.
Do category names really matter if the product pages are clean?
A category named for a goal tells the reader what every product in it is for. FDA has quoted headings and collection labels alongside product names, and they appear in breadcrumbs and URLs on every page beneath them.
SOURCES
Sources cited
Each source is listed with its class so government authority, agency guidance, enforcement examples, and private policy are never blended into one rule.
Quotes the blend name “CagriLean” and the outcome language around it.
Quotes listings that pair a dose with an approved brand name in the product title.
Quotes a “Standard Dose Protocol” label attached to a research-chemical listing.
Quotes product titles that carry per-milliliter doses.
Net impression is judged from the whole advertisement, including the product name and images.
Intended use is shown by labeling, advertising, and circumstances of distribution; a product name is labeling.